| Name | Title | Contact Details |
|---|
Multimatic Inc. is a Canadian company founded in 1984 and based in Markham, Ontario. It specializes in providing automotive components, systems, complete vehicles, and engineering services on a global scale. With manufacturing and engineering facilities across North America, Europe, and Asia-Pacific, Multimatic has evolved from producing basic automotive parts to offering advanced vehicle dynamics and niche vehicle production. The company operates through several divisions, including Multimatic Mechanisms, which manufactures hinge systems and powered closures, and Multimatic Structures & Suspension, known for structural components and advanced suspension systems. Multimatic Engineering supports product development and manufacturing, while the Niche Vehicles division focuses on low-volume, high-performance sports cars. Additionally, Multimatic Motorsports designs and builds race cars, contributing to the companys engineering advancements. Multimatic collaborates with major automotive brands such as Ford, Honda, Volkswagen, and Aston Martin, providing innovative solutions and expertise in the automotive industry.
Strategic Gears is the biggest local management consultancy firm in Saudi Arabia; It has offices in Egypt, Qatar and UK. Providing multidisciplinary services for both the private and public sectors. The company offers consulting solutions in the areas of Strategy, Marketing, Organizational Excellence and Digital, to a range of clients in both the public and private sectors. The company is heavily involved in the transformation era of Saudi Arabia, driven by the Vision 2030 initiatives. Strategic Gears prides itself on its ability to be a knowledge hub for the Saudi market, publishing reports on a monthly basis on the current state of the Kingdoms economy as well as hot topics in both the public and private sectors, including an annual coverage of the Saudi budget, and other reports on the Kingdoms macroeconomic performance, labour market, digital transformation and AI, among others. The company, which was founded in late 2015, has quickly evolved from a small team to more than 230 employees in all its branches.
World Athletics is the international governing body for athletics (track & field & running events). Our vision is to use the power and accessibility of athletics and our athletes to create a healthier and fitter world. World Athletics serves a number of stakeholders: professional athletes, their coaches, and their agents, and the 214 national athletics federations that make up the organisation, commercial partners and broadcasters. We work closely with the local organising committees to stage the biggest athletics events all over the world, to excite and engage with fans of all ages.
Estiatorio Milos is a renowned restaurant group founded in 1979 by Greek restaurateur Costas Spiliadis in Montreal. It is celebrated for its authentic Greek cuisine, emphasizing high-quality, fresh ingredients. With locations in major cities like New York, Athens, Las Vegas, Miami, London, Los Cabos, and Dubai, Milos offers refined dining experiences that prioritize simplicity and the art of sharing. The restaurant specializes in Mediterranean seafood, featuring fresh fish and shellfish sourced directly from Greek fishermen. Dishes are crafted to highlight natural flavors, often using artisanal ingredients like cold-pressed Koroneiki olive oil and seasonal vegetables. Milos is known for its warm hospitality and communal dining atmosphere, making it a favorite among discerning diners and culinary enthusiasts seeking an authentic taste of Greece.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.